Single-cell resolution that reveals what standard models miss
Problem
Preclinical tools can’t keep up with biological complexity
Even the most advanced drugs can fail—not because they miss the target, but because they behave unpredictably across different cell types.
This challenge, known as therapeutic pleiotropism, is rarely captured by traditional assays. Drugs interact with complex cellular systems, often activating one population while suppressing another. The outcome? Conflicting effects that standard models struggle to predict.
What we don’t measure, we can’t control
We realized that the most accessible and information-rich source of human biology—blood—was being underused. So we started with a simple idea: what if you could treat fresh human blood like a full-body sensor? By analyzing responses across all major blood cell types in parallel, we could start to see not just what a drug was designed to do, but what it actually does.
Dr. Lina Kovach
Arpelos Founder
“Too many drugs fail because we can’t see why.”
What we don’t measure, we can’t control
What began as a proof-of-concept evolved into a robust, scalable platform for capturing complex drug behavior in a format pharma teams can act on. Today, we’re combining single-cell resolution with functional profiling to bring clarity to one of the hardest problems in drug development—how to understand, predict, and design around therapeutic pleiotropism.
Step 1
Our approach
Start with blood. Keep it real.
We begin with fresh human blood, which contains a rich and clinically relevant mixture of immune, progenitor, and hematopoietic cells. These cells aren’t genetically engineered or isolated in artificial environments—they’re intact, functioning, and full of variability, just like in a real patient. This gives us a powerful foundation to study how drugs interact with the full immune landscape in its native form.
Step 3
Our approach
Inflammatory CD8+ T cell
Tfh/Tph CD4+ T cell
Bystander
T cell
B cell
From complexity to clarity.
We integrate these data into high-dimensional profiles that reveal a drug’s full cellular fingerprint. This systems-level insight helps researchers identify both desired effects and unexpected liabilities early in the pipeline—long before costly in vivo studies or clinical trials. The result is a deeper understanding of therapeutic potential, and a more rational,
data-driven path forward.
From fresh blood to functional insight
— in days, not months
We turn fresh human blood into a living model for drug respons —capturing how diverse cell types react in parallel. Our rapid, high-resolution workflow delivers functional readouts and cellular profiles in just days, helping teams move faster with more confidence.
Partnering
Let’s make your compounds more predictable.
We work with drug developers to profile preclinical candidates, de-risk discovery programs, and uncover new mechanisms of action. Whether you're advancing an early-stage biologic or optimizing a lead, we help you see what standard assays can’t.
Who we work with
We partner with R&D teams at global pharma companies, emerging biotechs, and translational researchers looking to deepen their understanding of drug behavior.
R&D teams at global pharma companies
Emerging biotechs exploring new therapeutic platforms
Translational researchers focused on immune or blood-based mechanisms
Preclinical groups seeking deeper mechanistic or safety insights
Flexible, collaborative, built for real-world questions
We work closely with partners to tailor each study—from early exploratory screens to targeted mechanistic programs. Our team brings both scientific depth and operational agility, making it easy to plug into your pipeline. Whether you’re de-risking a candidate or uncovering new opportunities, we’re here to help you move with clarity.
Contact us to learn more
STAY IN THE LOOP
Stay in the loop
as we build
what's next
Get occasional updates on our research, progress, and partnerships — no noise, just meaningful news from the Arpelos team.
Your email adress…
